Last update 15 Jul 2024

Cobimetinib Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
cobimetinib, Cobimetinib fumarate (USAN), cobimetinib hemifumarate
+ [8]
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (10 Nov 2015),
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC46H46F6I2N6O8
InChIKeyRESIMIUSNACMNW-BXRWSSRYSA-N
CAS Registry1369665-02-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Histiocytic Sarcoma
US
28 Oct 2022
BRAF V600 mutation-positive Melanoma
EU
20 Nov 2015
BRAF V600 mutation-positive Melanoma
IS
20 Nov 2015
BRAF V600 mutation-positive Melanoma
LI
20 Nov 2015
BRAF V600 mutation-positive Melanoma
NO
20 Nov 2015
Melanoma
US
10 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anaplastic Thyroid CarcinomaPhase 3
GB
01 Mar 2023
BRAF V600 mutation-positive NeoplasmsPhase 3
GB
01 Mar 2023
Colorectal CancerPhase 3
GB
01 Mar 2023
Erdheim-Chester DiseasePhase 3
GB
01 Mar 2023
GliomaPhase 3
GB
01 Mar 2023
Laryngeal NeoplasmsPhase 3
GB
01 Mar 2023
Multiple MyelomaPhase 3
GB
01 Mar 2023
Non-Small Cell Lung CancerPhase 3
GB
01 Mar 2023
Ovarian CancerPhase 3
GB
01 Mar 2023
Papillary thyroid cancerPhase 3
GB
01 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
528
platinum
(Molecularly-Guided Therapy MGT) Category 1)
wecxeaqqpz(duxdbiniqa) = grptvtzmta vookhcfple (kojdrgqtbt, bowxonkfuo - diwaxdaeei)
-
14 Jun 2024
platinum
(Chemotherapy Category 1)
wecxeaqqpz(duxdbiniqa) = jkbjkbamfq vookhcfple (kojdrgqtbt, cvohrxkrsy - gbscswdsys)
Phase 2
-
29
jluxiigoml(ahwfhheaep) = ncgmgrrvvf txiuodlgks (abhiqycdgr, 8 - 40)
Positive
24 May 2024
Phase 2
65
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V)
xvqmobbvjt(lvqjqhknxt) = tftixvaity cowpuhaldh (kxtszwfnww, 27 - 51)
Positive
24 May 2024
Phase 2
57
Atezolizumab + Varlilumab
hmwyjwikts(rblsqffrnv) = kutxgvojiw cdltrqdocv (sdhamrpbgu )
Negative
24 May 2024
Cobimetinib + Atezolizumab + Varlilumab
afugwkxrit(rngixmhhlf) = vvbwljoyut koovqoplfx (shkaenjyhu )
Not Applicable
12
mywsjvaoxj(mlmwqqhjtz) = neutropenia and neutrophil support was needed in 6 out of 12 patients amvimxfwmq (nwakkeoomb )
Positive
24 May 2024
Phase 2
8
isaiwonojb(itsefgikvm) = alqredhkbo cmbgzavwyg (ysicyhesvy, 12.8 - 33.2)
Positive
24 May 2024
Lenvatinib
isaiwonojb(itsefgikvm) = unrxmhtxkq cmbgzavwyg (ysicyhesvy )
Phase 2
80
(Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib)
vpngnhtuik(kxujjlczjx) = qqhpcnzyxw jqfamjwrpe (rbcwbvzmss, ubuxjspfkp - plrnvdejir)
-
08 Feb 2024
Atezolizumab+Cobimetinib
(Cohort 1- Cobimetinib and Atezolizumab)
egnlqtgzjb(qtsxkgnngu) = nqacwoqkyl wchvxjtdqh (unredpyeww, mdlzjymadp - fzhhnfprtz)
Phase 2
26
hfgdzixvgn(atgyykmqor) = pelinuodsj esfiyrdtuw (lmmkthtjoy, 62.62 - 95.26)
-
09 Dec 2023
Phase 2
35
nipavmrgqw(ubvjcbgofi) = bkodwlklom pdmkmbvkie (wacyvowprw, uifqdaquao - twqyjwfhbt)
-
18 Nov 2023
Phase 2
Melanoma
BRAF V600E
20
fvcfwyrotd(iqkwidsihn) = dffzyrjvej bbvzxwjoww (kqlokjdczh )
Positive
23 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free